Picodya Technologies is proud to announce the success of its recent demo day, held at our main labs, where we showcased the groundbreaking capabilities of our B-Matrix platform to investors and strategic partners. This event marked the conclusion of a rigorous proof-of-concept validation, demonstrating the platform’s ability to deliver high-performance diagnostics with precision and flexibility, further solidifying its value in the research market.

The demo day laid the groundwork for Picodya’s strategic expansion into the research domain, highlighted by the January 2024 installations of the B-Matrix platform at the prestigious Weizmann Institute of Science in Rehovot and the National Institute of Allergy and Infectious Diseases (NIAID) in Maryland. These milestones reflect the trust and enthusiasm of our collaborators as we continue to advance our mission of transforming diagnostics across both research and clinical settings.